Finding The Best Heart Disease And Stroke Treatments For Patients With Diabetes Using New Tool
Main Category: DiabetesAlso Included In: Statins; Heart Disease; IT / Internet / E-mail
Article Date: 30 Jun 2009 - 5:00 PST
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Researchers from North Carolina State University and Mayo Clinic have developed a computer model that medical doctors can use to determine the best time to begin using statin therapy in diabetes patients to help prevent heart disease and stroke.
"The research is significant because patients with diabetes are at high risk for cardiovascular disease and statins are the single most commonly used treatment for patients at risk of heart disease and/or stroke," says Dr. Brian Denton, "and this model can help determine the best course of action for individual patients based on their risk of developing cardiovascular disease." Denton is an assistant professor in NC State's Edward P. Fitts Department of Industrial & Systems Engineering and lead author of the study.
Statins are a key component of current cardiovascular medical treatment guidelines, Denton says. They lower cholesterol levels and may significantly reduce the risk of heart attack and stroke, particularly in patients that are considered to be at high risk.
The researchers developed a new mathematical model that examines various possible treatment policies to see how they influence short-term and long-term health outcomes for patients. The model shows how people are affected by diabetes, and how their health changes over time as the disease advances and patients age.
The new model incorporates patient-specific data. An established risk model calculates each patient's probability of heart attack and stroke based on risk factors, such as their cholesterol, blood pressure, etc. This overall risk "score" is used to weigh the medical advantages of beginning statin therapy against the financial cost of the statins.
Overall, by accounting for the progression of diabetes, the patient's specific risk score and the cost-benefit analysis, the new model may help patients and doctors decide on the optimal time to begin statin therapy.
Denton says the new model has not yet been put into practice, but that the research team plans to develop a pilot to put the tool into the hands of medical professionals.
The research, "Optimizing the Start Time of Statin Therapy for Patients with Diabetes," was funded in part by the Agency for Healthcare Research and Quality and the National Science Foundation, and was published earlier this month in the journal Medical Decision Making. The research was co-authored by Denton from NC State; Nilay D. Shah, Sandra C. Bryant and Steven A. Smith of the Mayo Clinic College of Medicine; and University of Pittsburgh graduate student Murat Kurt.
Source:
Matt Shipman
North Carolina State University
Visit our diabetes section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/155840.php>
APA
http://www.medicalnewstoday.com/releases/155840.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




